retatrutide positive effects Lindsay Maggio, MD, MPH | 📣 News you need to know — is almost here, and the data is remarkable. Eli Lilly just released Phase 3 results for retatrutide, Retatrutide UK 2026: Phase 3

Nonetheless, investigators from the Canadian Network for Observational Drug Effect Studies (CNODES) reported contradictory results

If the manufacturer wins the patent challenge, generic semaglutide could enter the market years earlier than the patent expiration dates listed above

At the highest dose (36 mg/day), orforglipron led to an average weight loss of 11.2% over 72 weeks

2 Majority of patients were treated with standard of care 1,2,n,o Summary of medication at baseline (N=3533) 1,2 Select CV and CKD baseline characteristics (N=3533) 1,2 n At baseline patients in FLOW were receiving standard-of-care background therapy, including a maximum tolerated label dose of a RAAS-blocking agent including an ACE inhibitor or an ARB, unless such treatment was contraindicated or not tolerated

Faillie JL, Yin H, Ohy Y, et al

Pharmacological treatments for fatigue in patients with multiple sclerosis: a systematic review and meta-analysis